Cullinan Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Cullinan Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders online on June 26, 2024, to elect directors and ratify auditors.</b>

AI Summary

Cullinan Therapeutics, Inc. (CGEM) filed a Proxy Statement (DEF 14A) with the SEC on May 16, 2024. The 2024 Annual Meeting of Stockholders for Cullinan Therapeutics, Inc. will be held online on June 26, 2024, at 10:00 a.m. Eastern Time. The meeting agenda includes the election of two Class I directors: Anne-Marie Martin and David Meek, for three-year terms. Stockholders will vote on the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Proxy materials are accessible and voting can be done online at www.ProxyVote.com. The company was formerly known as Cullinan Oncology, Inc., with a name change effective February 25, 2021.

Why It Matters

For investors and stakeholders tracking Cullinan Therapeutics, Inc., this filing contains several important signals. This filing is a Definitive Proxy Statement (DEF 14A), indicating it contains important information for shareholders regarding the upcoming annual meeting and voting procedures. The virtual format of the meeting aims to increase stockholder participation by allowing remote access at no cost.

Risk Assessment

Risk Level: low — Cullinan Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational disclosures that would indicate significant risk.

Analyst Insight

Stockholders should review the proxy materials and vote on the proposed director elections and auditor ratification before the June 26, 2024 meeting.

Key Numbers

• 2 — Directors to be elected (Two Class I directors will be elected at the meeting.)
• 3 — Director term length (Elected directors will serve three-year terms.)
• 2024 — Fiscal year for auditor (KPMG LLP is proposed as auditor for the fiscal year ending December 31, 2024.)
• 10:00 a.m. Eastern Time — Meeting time (The virtual meeting will commence at this time.)

Key Players & Entities

• Cullinan Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
• KPMG LLP (company) — Proposed independent registered public accounting firm.
• Anne-Marie Martin (person) — Nominee for Class I director.
• David Meek (person) — Nominee for Class I director.
• Cullinan Oncology, Inc. (company) — Former name of the registrant.
• 2024 (date) — Year of the Annual Meeting.
• June 26, 2024 (date) — Date of the Annual Meeting.
• 20240516 (date) — Filing date of the document.

FAQ

Industry Context

Cullinan Therapeutics, Inc. operates in the biotechnology sector, focusing on developing therapies. This filing is a standard proxy statement for its annual shareholder meeting.

Regulatory Implications

The filing is made under SEC Rule 14a-101, which governs the information required in proxy statements for shareholder meetings.

What Investors Should Do

1. Review the proxy materials for the 2024 Annual Meeting.
2. Vote on the election of Class I directors Anne-Marie Martin and David Meek.
3. Vote on the ratification of KPMG LLP as the independent registered public accounting firm.

Key Dates

• 2024-06-26: 2024 Annual Meeting of Stockholders — Key date for stockholder voting on directors and auditors.
• 2024-05-16: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Year-Over-Year Comparison

This is a Definitive Proxy Statement (DEF 14A) for the 2024 Annual Meeting, following the company's previous filings.

Key Financial Figures

• $1.235 billion — gross revenue is equal to or more than $1.235 billion; (iii) the date on which we have issued
• $1.0 billion — date on which we have issued more than $1.0 billion in nonconvertible debt during the previ
• $0.0001 — 4 shares of our common stock, par value $0.0001 per share, outstanding on April 29, 202

Filing Documents

• d929103ddef14a.htm (DEF 14A) — 349KB
• g929103g00a11.jpg (GRAPHIC) — 238KB
• g929103g00a22.jpg (GRAPHIC) — 210KB
• g929103g15p03.jpg (GRAPHIC) — 39KB
• 0001193125-24-139976.txt (&nbsp;) — 1021KB

From the Filing

DEF 14A 1 d929103ddef14a.htm DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 CULLINAN THERAPEUTICS, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Table of Contents May 16, 2024 Dear Cullinan Stockholder: I am pleased to invite you to attend the 2024 Annual Meeting of Stockholders (the Annual Meeting) of Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (the Company). The meeting will be held online on June 26, 2024 at 10:00 a.m. Eastern Time. The Annual Meeting will be a virtual meeting in order to facilitate stockholder attendance and participation by enabling stockholders to participate from any location and at no cost to the stockholder. The meeting will be conducted via live webcast. Details regarding admission to the Annual Meeting and the business to be conducted are more fully described in the accompanying Notice of Internet Availability of Proxy Materials (Notice of Availability) and Proxy Statement. At the Annual Meeting, the agenda includes: the election of two (2) Class I directors, Anne-Marie Martin and David Meek, each for a three-year term until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal; the ratification of the appointment of KPMG LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2024; and the transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. Under Securities and Exchange Commission rules, the Company is providing access to the proxy materials for the Annual Meeting to stockholders via the Internet. Accordingly, you can access the proxy materials and vote at www.ProxyVote.com. Instructions for accessing the proxy materials and voting are described below and in the Notice of Availability that you received in the mail. Your vote is very important. Whether or not you plan to virtually attend the Annual Meeting, please carefully review the enclosed proxy statement and then cast your vote, regardless of the number of shares you hold. If you are a stockholder of record, you may vote over the Internet, by telephone, by mail, or, if you request to receive a printed set of the proxy materials, by following the directions on the Notice of Availability. Submitting your vote via the Internet or by telephone or proxy card will not affect your right to vote during the meeting if you decide to virtually attend the Annual Meeting. If your shares are held in street name (held for your account by a broker or other nominee), you will receive instructions from your broker or other nominee explaining how to vote your shares, and you will have the option to cast your vote by telephone or over the Internet if the voting instruction form from your broker or nominee includes instructions and a toll-free telephone number or Internet website to do so. In any event, to be sure that your vote will be received in time, please cast your vote by your choice of available means at your earliest convenience. We hope that you will join us on June 26, 2024. Your investment and continuing interest in the Company are very much appreciated. Sincerely, /s/ Nadim Ahmed Nadim Ahmed President and Chief Executive Officer Table of Contents NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS Time 10:00 a.m., Eastern Time Date Wednesday, June 26, 2024 Place Virtual. Details on how to participate are described in the Notice of Availability or by visiting www.ProxyVote.com. Purpose To elect Anne-Marie Martin and David Meek as Class I directors of the Board of Directors, to serve until the Companys 2027 Annual Meeting of Stockholders and until her or his successor is duly elected and qualified; To ratify the appointment of KPMG as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2024; and To transact any other business that may properly come before the meeting or any adjournment thereof. Record Date The Board of Directors has fixed the close of business o

View Full Filing

View this DEF 14A filing on SEC EDGAR